Raja Sanjeev Kumar Nakka | Immunology and Microbiology | Best Researcher Award

Mr. Raja Sanjeev Kumar Nakka | Immunology and Microbiology | Best Researcher Award

Ragon Institute of MGH, MIT and Harvard | United States

Mr. Rajasanjeev Kumar Nakka is a highly accomplished software engineer and data analyst with over a decade of experience in computer programming, software development, data analytics, and systems design. His career spans a broad spectrum of domains, including enterprise application development, data management, system optimization, and scientific computing, with hands-on expertise in C#, ASP.NET, Java, SQL, and data-driven web technologies. A results-oriented technologist, he is recognized for his ability to transform complex business requirements into robust, scalable, and efficient software solutions across industries ranging from financial systems to biomedical informatics. Mr. Nakka holds a Master of Science in Computer Science from Kansas State University, USA (2007), and a Bachelor of Technology in Computer Science and Engineering from Acharya Nagarjuna University, India (2005). In addition, he is a Microsoft Certified Professional Developer (MCPD) and a Sun Certified Java Programmer (SCJP), affirming his proficiency in advanced programming paradigms and software engineering principles. His continuous learning ethos is reflected in certifications spanning data science, software testing, machine learning, and cybersecurity, underscoring his commitment to professional growth and technological innovation. Throughout his distinguished career, Mr. Nakka has contributed significantly to several high-impact software projects. At the Ragon Institute of MGH, MIT, and Harvard, he currently serves as a Senior Data Analyst, leading the development of the Cellular Immunology Database (CIDB)—a sophisticated data management system integrating genetic, clinical, immunological, and virological datasets to support HIV/AIDS research and vaccine development. His role extends beyond technical development to include project management, computational design, stakeholder engagement, and cross-functional collaboration with leading biomedical researchers. His work has enabled efficient data flow, secure information sharing, and advanced analytical capabilities within one of the world’s foremost medical research institutions. Previously, as a Senior Software Engineer at Confluence (Indecomm Global Services) in Pittsburgh, USA, Mr. Nakka was instrumental in developing and supporting SaaS-enabled financial platforms, including Unity NXT for budgeting, expense management, and fund reporting. His technical leadership in employing ASP.NET MVC, JQuery, Knockout, and CQRS frameworks contributed to enhanced system reliability, scalability, and maintainability. His earlier tenure at CDC Software (India) involved designing and implementing CRM integration systems for Microsoft Office, improving workflow synchronization and user experience for global clients. Mr. Nakka’s early career at CivicPlus (USA) and as a Graduate Teaching Assistant at Kansas State University provided a strong foundation in web architecture, software design, and database engineering, including projects that evaluated J2EE and .NET performance for enterprise web services. His academic and industrial projects have consistently demonstrated strong analytical thinking, attention to quality, and a balance between innovation and practical implementation. Driven by curiosity, precision, and innovation, Mr. Rajasanjeev Kumar Nakka continues to advance the integration of data science, software engineering, and computational intelligence, empowering institutions and industries to harness technology for smarter, data-informed decision-making and impactful digital transformation.

Profiles: OrcidGoogle Scholar 

Featured Publications

Lampou, M., Trull, E. C., Warren, H. M., Ghebremichael, M. S., Nakka, R., Floyd, D. J., et al. (2025). Clinical utility of plasma microbial cell-free DNA surveillance in neutropenic patients with acute myeloid leukemia undergoing outpatient chemotherapy: A case series. Diagnostics, 15(13), 1715. https://doi.org/10.3390/diagnostics15131715

Gandla, S., Nakka, R., Khan, R. A., Salboukh, F., & Ghebremichael, M. (2025). The association between syphilis infection and HIV acquisition and HIV disease progression in Sub-Saharan Africa. Tropical Medicine and Infectious Disease, 10(3), 65. https://doi.org/10.3390/tropicalmed10030065

Gandla, S., Nakka, R., Khan, R. A., Bose, E., & Ghebremichael, M. (2025). Biological and social predictors of HIV-1 RNA viral suppression in ART treated PWLH in Sub-Saharan Africa. Tropical Medicine and Infectious Disease, 10(1), 24. https://doi.org/10.3390/tropicalmed10010024

Irie, W. C., Mahone, A., Nakka, R., & Ghebremichael, M. (2023). Factors associated with comfort discussing PrEP with healthcare providers among Black cisgender women. Tropical Medicine and Infectious Disease, 8(9), 436. https://doi.org/10.3390/tropicalmed8090436

Irie, W., Mahone, A., Nakka, R., & Ghebremichael, M. (2023). Confidence in ability to communicate with sexual partners about PrEP among Black cisgender women. AIDS Education and Prevention, 35(5), 333–346. https://doi.org/10.1521/aeap.2023.35.5.333

Vasudeva, M., Nakka, R., Stock, S., & Ghebremichael, M. (2022). Associations between awareness of sexually transmitted infections (STIs) and prevalence of STIs among Sub-Saharan African men and women. Tropical Medicine and Infectious Disease, 7(8), 147. https://doi.org/10.3390/tropicalmed7080147

Soumitra Moulick | Microbiology | Best Researcher Award | 13395

Mr. Soumitra Moulick | Microbiology | Best Researcher Award

Mr. Soumitra Moulick, TCG Lifesciences Pvt. Ltd., India

Mr. Soumitra Moulick, Lead Scientist at TCG Lifesciences Pvt. Ltd., brings over 18 years of expertise in drug discovery research, with impactful contributions in antimicrobial, anti-inflammatory, and anticancer therapeutics. Currently pursuing a PhD at NIT Raipur, he has published peer-reviewed papers and is engaged in an ICMR-funded project on antibiotic-resistant E. coli. His work has supported over 15 global collaborations with pharmaceutical leaders, earning recognition including a best poster award at IIIT Allahabad. His consistent commitment to innovation and translational science underscores his suitability for the Best Researcher Award.

Profile

Scopus

🎓 Early Academic Pursuits

Mr. Soumitra Moulick embarked on his academic journey with a Master’s degree from a reputed Indian university, laying a strong foundation in life sciences and pharmacological research. From the beginning, his keen interest in drug discovery and therapeutic development drove him to pursue in-depth studies in microbiology, pharmacology, and biochemistry. His academic dedication was further demonstrated when he enrolled in a PhD program at the prestigious National Institute of Technology (NIT), Raipur, where he continues to explore advanced research in antibacterial drug discovery. His early education equipped him with a robust scientific mindset and set the stage for a dynamic career in the pharmaceutical sector.

🧪 Professional Endeavors

Mr. Moulick has devoted over 18 years of his professional life to TCG Lifesciences Pvt. Ltd., Kolkata, one of India’s leading Contract Research Organizations (CROs). Rising through the ranks, he currently serves as a Lead Scientist in the In-vitro Pharmacology Department. In this role, he has led and collaborated on more than 15 drug discovery projects, targeting diseases in the therapeutic areas of oncology, infectious diseases, and inflammation.

His work spans protocol development, in-vitro screening, target validation, and assay optimization. Mr. Moulick has worked closely with world-renowned pharmaceutical companies such as Pfizer, Roche, Takeda, Grunenthal, MMV, and DNDi, showcasing his ability to integrate scientific rigor with industry demands. His career at TCG Lifesciences stands as a testament to his commitment, technical excellence, and leadership in translational research.

🔬 Contributions and Research Focus

Mr. Moulick’s primary research interests lie in antimicrobial resistance (AMR), anti-inflammatory therapeutics, and oncology drug discovery. His doctoral research focuses on antibiotic-resistant Escherichia coli, a major causative agent of urinary tract infections. This work is supported by the Indian Council of Medical Research (ICMR) under Grant No. DDR/IIRP23/0569.

He has already published two peer-reviewed research articles in reputed journals such as Microbial Drug Resistance and Microbial Pathogenesis. Despite the limitations on publishing often faced in CRO environments, Mr. Moulick has successfully balanced industry confidentiality with academic contribution. His scientific research emphasizes innovation, with a focus on identifying novel molecular targets, validating high-throughput screening methodologies, and exploring natural and synthetic compound libraries for drug efficacy.

🏅 Accolades and Recognition

Mr. Moulick’s contributions have not gone unnoticed. His poster presentation at the International Webinar cum Workshop on Recent Developments in Applied Biotechnology (organized by IIIT Allahabad) was honored with a Best Poster Award, reflecting the academic community’s recognition of his impactful research.

One of his recent publications received a provisional selection for the “Best Researcher Award”, further validating the significance and originality of his scientific output. In addition to this, he is currently in the process of contributing a book chapter, and he has one patent under review, indicating his continued engagement in knowledge creation and technology transfer.

🌍 Impact and Influence

Over nearly two decades, Mr. Moulick has significantly influenced both industry and academic research through his extensive project experience and collaborative spirit. His ability to work with global pharmaceutical giants has not only enhanced the credibility of Indian CROs but also brought innovative therapeutic candidates closer to clinical application.

His research on antibiotic resistance has real-world implications, particularly in the context of rising multidrug-resistant infections. By identifying alternative treatment strategies and molecular targets, Mr. Moulick’s work contributes meaningfully to public health and global medicine. His influence extends across laboratories, boardrooms, and academic institutions, as he frequently engages in collaborative projects that bridge academia and industry.

🌟 Legacy and Future Contributions

Looking ahead, Mr. Moulick is poised to further strengthen his contributions to drug discovery and biomedical innovation. His future endeavors include completing his PhD with a high-impact third publication, finalizing his patent application, and authoring a comprehensive book chapter that can serve as a resource for young researchers and professionals.

He aims to mentor early-career scientists in preclinical research and build a legacy of scientific excellence, collaboration, and integrity. With a vision to drive innovative, affordable, and accessible therapeutics, Mr. Moulick is committed to being a catalyst for change in the Indian and global pharmaceutical landscape.

His unique blend of academic rigor, industrial experience, and collaborative mindset makes him a valuable contributor to the scientific community, and his nomination for the Best Researcher Award is both timely and well-deserved.

Publication Top Notes

Author: S., Moulick, Soumitra, D.N., Roy, Dijendra Nath

Journal: Microbial Pathogenesis

Year: 2025

Bioflavonoid Baicalein Modulates Tetracycline Resistance by Inhibiting Efflux Pump in Staphylococcus aureus

Author: Soumitra Moulick and Dijendra Nath Roy

Journal: Microbial Drug Resistance

Year: 2024